BioDirection Closes $4M Series B Financing

BioDirection has closed about $4 million in a Series B convertible preferred stock financing, the company announced.

The financing will be used to support final stages of developing traumatic brain injury test technology, designed to aid in the diagnosis of concussions and other brain injuries in less than 90 seconds at point-of-care.

With the Series B round, the total funds raised by the company are roughly $10 million. — Jonathon Shacat